Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-15T06:37:40.545Z Has data issue: false hasContentIssue false

Chapter 47 - Maintenance Therapy in Plasma Cell Myeloma after Autologous Transplant

from Section 13 - Plasma Cell Dyscrasias: Hematopoietic Cell Transplants

Published online by Cambridge University Press:  24 May 2017

By
Sarah A. Holstein  and
Philip L. McCarthy
Edited by
Hillard M. Lazarus ,
Robert Peter Gale ,
Armand Keating ,
Andrea Bacigalupo ,
Reinhold Munker  and
Kerry Atkinson
Edited in association with
Syed Ali Abutalib
Hillard M. Lazarus
Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale
Affiliation:
Imperial College London
Armand Keating
Affiliation:
University of Toronto
Andrea Bacigalupo
Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker
Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson
Affiliation:
University of Queensland
Syed Ali Abutalib
Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago
Get access
Type
Chapter
Information
Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
 , pp. 458 - 467
Publisher: Cambridge University Press
Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Palumbo, A, Gay, F, Falco, P et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 28(5), 800–807 (2010).CrossRefGoogle ScholarPubMed
McCarthy, PL, Owzar, K, Hofmeister, CC et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19), 1770–1781 (2012).CrossRefGoogle ScholarPubMed
Holstein, SA, Owzar, K, Richardson, PG, et al. Updated analysis of CALGB/ECOG/BMT CTN 100104: lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma. J Clin Oncol. 2015;33(suppl) abstract 8523.CrossRefGoogle Scholar
Attal, M, Lauwers-Cances, V, Marit, G et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366(19), 1782–1791 (2012).CrossRefGoogle ScholarPubMed
Attal, M, Lauwers-Cances, V, Marit, G et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005–02 Trial. Blood 122(21), 406 (2013).CrossRefGoogle Scholar
Palumbo, A, Cavallo, F, Caravita, T et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371(10), 895–905 (2014).CrossRefGoogle ScholarPubMed
Attal, M, Palumbo, A, Holstein, SA, et al. Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a meta-analysis (MA) of overall survival (OS). J Clin Oncol 34(suppl), abstract 8001 (2016).CrossRefGoogle Scholar
McCarthy, PL, Einsele, H, Attal, M, Giralt, S. The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients. Expert Rev Hematol 7(1), 55–66 (2014).CrossRefGoogle ScholarPubMed
McCarthy, PL, Owzar, K, Anderson, KC et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104. ASH Annual Meeting Abstracts 116(21), 37 (2010).Google Scholar
Attal, M, Lauwers, VC, Marit, G et al. Maintenance treatment with lenalidomide after transplantation for myeloma: final analysis of the IFM 2005–02. ASH Annual Meeting Abstracts 116(21), 310 (2010).Google Scholar
Tzeng, HE, Lin, CL, Tsai, CH et al. Time trend of multiple myeloma and associated secondary primary malignancies in Asian patients: a Taiwan population-based study. PLoS One 8(7), e68041 (2013).CrossRefGoogle ScholarPubMed
Razavi, P, Rand, KA, Cozen, W, Chanan-Khan, A, Usmani, S, Ailawadhi, S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J 3, e121 (2013).CrossRefGoogle ScholarPubMed
Mailankody, S, Pfeiffer, RM, Kristinsson, SY et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 118(15), 4086–4092 (2011).CrossRefGoogle ScholarPubMed
Krishnan, AY, Mei, M, Sun, CL et al. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 19(2), 260–265 (2013).CrossRefGoogle ScholarPubMed
Usmani, SZ, Sexton, R, Hoering, A et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood 120(8), 1597–1600 (2012).CrossRefGoogle ScholarPubMed
Rossi, A, Mark, T, Jayabalan, D et al. BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma. Blood 121(11), 1982–1985 (2013).CrossRefGoogle ScholarPubMed
Fouquet, G, Tardy, S, Demarquette, H et al. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer 119(20), 3680–3686 (2013).CrossRefGoogle ScholarPubMed
Palumbo, A, Larocca, A, Zweegman, S et al. Second primary malignancies in newly diagnosed multiple myeloma patients treated with lenalidomide: analysis of pooled data in 2459 patients. ASH Annual Meeting Abstracts 118(21), 996 (2011).Google Scholar
Palumbo, A, Bringhen, S, Kumar, SK et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol 15(3), 333–342 (2014).CrossRefGoogle ScholarPubMed
Sonneveld, P, Schmidt-Wolf, IG, Van Der Holt, B et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 30(24), 2946–2955 (2012).CrossRefGoogle ScholarPubMed
Mellqvist, U-H, Gimsing, P, Hjertner, O et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood 121(23), 4647–4654 (2013).CrossRefGoogle Scholar
Straka, C, Vogel, M, Muller, J, et al. Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM). J Clin Oncol 33(suppl), abstract 8511 (2015).CrossRefGoogle Scholar
Rosinol, L, Oriol, A, Teruel, AI et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 120(8), 1589–1596 (2012).CrossRefGoogle ScholarPubMed
Cavo, M, Tacchetti, P, Patriarca, F et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 376(9758), 2075–2085 (2010).CrossRefGoogle ScholarPubMed
Barlogie, B, Anaissie, E, Van Rhee, F et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 138(2), 176–185 (2007).CrossRefGoogle ScholarPubMed
San Miguel, JF, Schlag, R, Khuageva, NK et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31(4), 448–455 (2013).CrossRefGoogle ScholarPubMed
Avet-Loiseau, H, Caillot, D, Marit, G et al. Long-term maintenance with lenalidomide improves progression free survival in myeloma patients with high-risk cytogenetics: an IFM study. ASH Annual Meeting Abstracts 116(21), 1944 (2010).Google Scholar
Avet-Loiseau, H, Leleu, X, Roussel, M et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28(30), 4630–4634 (2010).CrossRefGoogle Scholar
Jagannath, S, Richardson, PG, Sonneveld, P et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 21(1), 151–157 (2007).CrossRefGoogle ScholarPubMed
Scheid, C, Sonneveld, P, Schmidt-Wolf, IG et al. Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 99(1), 148–154 (2014).CrossRefGoogle ScholarPubMed
Neben, K, Lokhorst, HM, Jauch, A et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 119(4), 940–948 (2012).CrossRefGoogle ScholarPubMed
Nooka, AK, Kaufman, JL, Muppidi, S et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia 28(3), 690–693 (2014).CrossRefGoogle ScholarPubMed
Nair, B, Van Rhee, F, Shaughnessy, JD Jr. et al. Superior results of Total Therapy 3 (2003–33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006–66 with VRD maintenance. Blood 115(21), 4168–4173 (2010).CrossRefGoogle ScholarPubMed
Van De Velde, HJ, Liu, X, Chen, G, Cakana, A, Deraedt, W, Bayssas, M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92(10), 1399–1406 (2007).CrossRefGoogle ScholarPubMed
Paiva, B, Vidriales, MB, Cervero, J et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10), 4017–4023 (2008).CrossRefGoogle ScholarPubMed
Rawstron, AC, Child, JA, De Tute, RM et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 31(20), 2540–2547 (2013).CrossRefGoogle ScholarPubMed
Kvam, AK, Fayers, P, Hjermstad, M, Gulbrandsen, N, Wisloff, F. Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations. Eur J Haematol 83(4), 279–289 (2009).CrossRefGoogle ScholarPubMed
Stewart, AK, Trudel, S, Bahlis, NJ et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood 121(9), 1517–1523 (2013).CrossRefGoogle ScholarPubMed
Burnette, BL, Dispenzieri, A, Kumar, S et al. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. Cancer 119(24), 4308–4315 (2013).CrossRefGoogle ScholarPubMed
Rawstron, AC, Davies, FE, Dasgupta, R et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 100(9), 3095–3100 (2002).CrossRefGoogle ScholarPubMed
Paiva, B, Martinez-Lopez, J, Vidriales, MB et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol 29(12), 1627–1633 (2011).CrossRefGoogle ScholarPubMed
Van Der Velden, VH, Cazzaniga, G, Schrauder, A et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4), 604–611 (2007).CrossRefGoogle ScholarPubMed
Puig, N, Sarasquete, ME, Balanzategui, A et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 28(2), 391–397 (2014).CrossRefGoogle ScholarPubMed
Sarasquete, ME, Garcia-Sanz, R, Gonzalez, D et al. Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry. Haematologica 90(10), 1365–1372 (2005).Google ScholarPubMed
Puig, N, Sarasquete, ME, Alcoceba, M et al. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. Ann Hematol 92(1), 97–100 (2013).CrossRefGoogle ScholarPubMed
Faham, M, Zheng, J, Moorhead, M et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 120(26), 5173–5180 (2012).CrossRefGoogle ScholarPubMed
Martinez-Lopez, J, Lahuerta, JJ, Pepin, F et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 123(20), 3073–3079 (2014).CrossRefGoogle ScholarPubMed
Paiva, B, Gutierrez, NC, Rosinol, L et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood 119(3), 687–691 (2012).CrossRefGoogle ScholarPubMed
Putkonen, M, Kairisto, V, Juvonen, V et al. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma. Eur J Haematol 85(5), 416–423 (2010).CrossRefGoogle ScholarPubMed
Kumar, S, Paiva, B, Anderson, KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8), e328–e346 (2016).CrossRefGoogle Scholar
Paiva, B, Vidriales, MB, Cervero, J, et al. Multiparametric flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112(10), 4017–23 (2008).Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×